We are proud to announce the receipt of funding for the project entitled “TACTIC – TCR-T And TCR-based CAR-T Cell Therapies: new opportunities in the treatment of acute myeloid leukemia”, led by Dr Emilia Jaskuła PhD from the Laboratory of Genetics and Epigenetics of Human Diseases. The project was submitted in the competition of the Medical Research Agency for scientific units for the implementation of applied research in the biomedical area (2024/ABM/03/KPO) within the framework of the National Plan for Rehabilitation and Enhancement of Immunity and received funding in the amount of PLN 14 592 945.41.
The TACTIC project aims to develop innovative TCR-T and TCR-based CAR-T cell therapies against acute myeloid leukaemia (AML). These therapies are based on genetically modified T-lymphocytes that are capable of accurately recognising and destroying tumour cells while reducing the risk of damage to healthy tissues. The project’s work includes the selection of therapeutic targets, the optimisation of TCR receptor sequences, and the development and testing of genetically modified T cells in a preclinical setting. The ultimate outcome of the project will be to lay the groundwork for future clinical trials that will bring us closer to bringing this innovative therapy to the treatment of patients with AML.